Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255707 | 0.83 | KDM4E (0.56) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6253153 | 0.82 | KDM4E (0.58) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL15131077 | 0.79 | KDM4E (0.60) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6252685 | 0.78 | KDM4E (0.65) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL2704412 | 0.78 | KDM4E (0.65) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6255863 | 0.78 | KDM4E (0.58) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL7048944 | 0.76 | KDM4E (0.63) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6253276 | 0.76 | KDM4E (0.60) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6252449 | 0.76 | KDM4E (0.60) | KDM4EPRMT5ALDH1A1KMT2A | |
| SCHEMBL6254240 | 0.75 | TAS1R3 (0.56) | KDM4EPRMT5ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | ABBOTT LABORATORIES | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | KDM4E 3624/4885PRMT5 2776/4885ALDH1A1 404/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | KDM4E 3321/4885PRMT5 2867/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.